Alnylam Pharmaceuticals makes four senior appointments

American biotech firm Alnylam Pharmaceuticals (Nasdaq: ALNY) has made several new appointments to its senior management team.

The company, which is focused on developing RNA interference therapeutics for genetic diseases, has appointed Manmeet Soni as chief financial officer, Theresa Heggie as head of Europe and Canada, Peter Smith as head of early development and Alan Eisenberg as head of global public policy and government relations.

Chief executive John Maraganore said: "We are thrilled to welcome Manmeet, Theresa, Peter, and Alan to Alnylam at an exciting moment in our history.”